Risks and benefits of oral HIV pre-exposure prophylaxis for people with chronic hepatitis B - IRD - Institut de recherche pour le développement Accéder directement au contenu
Article Dans Une Revue The Lancet HIV Année : 2022

Risks and benefits of oral HIV pre-exposure prophylaxis for people with chronic hepatitis B

Résumé

Individuals with chronic hepatitis B virus (HBV) infection who are at substantial risk of HIV acquisition benefit from pre-exposure prophylaxis (PrEP) with tenofovir-based antiviral therapy. Considering that tenofovir potently inhibits HBV, providing PrEP to individuals with HBV effectively results in treatment of their HBV infection. However, some clinicians might be hesitant to initiate PrEP in people with chronic HBV due to unknown risks of HBV reactivation, hepatitis, and acute liver failure during periods of antiviral cessation. Unfortunately, these knowledge gaps affect scale up of PrEP among people with chronic HBV. Emerging data regarding the risks and benefits of antiviral cessation in people with chronic HBV suggest that PrEP can be safely initiated despite the risks of non-adherence or discontinuation. People with chronic HBV who stop PrEP should be closely monitored for HBV reactivation and hepatitis flares after antiviral cessation.

Mots clés

Fichier principal
Vignette du fichier
010086363.pdf (806.74 Ko) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

ird-03879814 , version 1 (30-11-2022)

Identifiants

Citer

Amir M Mohareb, Joseph Larmarange, Arthur Y Kim, Patrick A Coffie, Menan Gérard Kouamé, et al.. Risks and benefits of oral HIV pre-exposure prophylaxis for people with chronic hepatitis B. The Lancet HIV, 2022, Lancet HIV, 9 (8), pp.e585-e594. ⟨10.1016/S2352-3018(22)00123-0⟩. ⟨ird-03879814⟩
90 Consultations
12 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More